Danish biotech company Egalet appoints new chairman and new CEO

05-Sep-2007

The Board of Directors of the Danish specialty pharmaceutical company Egalet and the company's principal shareholders have asked Michael Fiorini to step in as the company's new chairman. Michael Fiorini, replaces Egalet's existing chairman, Seppo Mäkinen of Bio Fund Management ltd, who has chaired the board since 2005. Egalet has also appointed Peter Nordkild, formerly Chief Commercial Officer of Pharmexa, as Chief Executive Officer.

Michael Fiorini (59) is the former CEO of The East Asiatic Company and a senior executive with A.P. Møller Mærsk.

Seppo Mäkinen remains a member of Egalet's board of directors with Regina Hodits, Atlas Venture, Francesco De Rubertis, Index Ventures and Jan-Eric Österlund, QueQuoin Holdings.

In addition, Egalet has employed Peter Nordkild (52) as its new Chief Executive Officer. Peter Nordkild was previously Chief Commercial Officer of the listed Danish biotech company Pharmexa. Before joining Pharmexa, he held a position as Senior Vice President with Ferring Pharmaceuticals..

Peter Nordkild will supersede Jan Quistgaard, a co-founder and co-owner of Egalet, during September. Jan Quistgaard will continue as external advisor to the management of Egalet.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances